Comparison of five staging systems in hepatocellular carcinoma treated with sorafenib: A single-center experience

  • Authors:
    • Masatsugu Endo
    • Hiroki Nishikawa
    • Ryuichi Kita
    • Toru Kimura
    • Yoshiaki Ohara
    • Azusa Sakamoto
    • Sumio Saito
    • Norihiro Nishijima
    • Akihiro Nasu
    • Hideyuki Komekado
    • Yukio Osaki
  • View Affiliations

  • Published online on: January 28, 2016     https://doi.org/10.3892/mco.2016.755
  • Pages: 515-522
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

To the best of our knowledge, none of the prognostic staging systems for hepatocellular carcinoma (HCC) patients who underwent sorafenib therapy is universally adopted or preferred. In the present study, we aimed to compare prognostic ability among five prognostic systems, including the Japan integrated staging (JIS) system, the Barcelona Clinic Liver Cancer classification system, the tumor‑node‑metastasis classification system, the Cancer of the Liver Italian Program scoring system and the Chinese university prognostic index (CUPI) scoring system for HCC patients who received sorafenib therapy. A total of 143 HCC patients treated with sorafenib were analysed. We compared prognostic ability among the five prognostic systems using the likelihood ratio (LR) χ2 test, linear trend χ2 test and concordance index (c-index). Our cohort included 114 men and 29 women. The median patient age was 71 years (range, 45-89 years). A total of 102 patients were classified as Child-Pugh A and 41 as Child‑Pugh B, whereas 31 patients (21.7%) had portal vein invasion and 63 (44.1%) extrahepatic metastases. The median survival time was 6.9 months. In the LR χ2 test, the CUPI scoring system had the highest value (35.804), followed by the JIS system (17.469). In the linear trend χ2 test, the CUPI scoring system had the highest value (17.523), followed by the JIS system (15.819). In addition, the JIS system had the highest value in the 6‑month c-index (0.659) as well as in the 1‑year c-index (0.674). However, the CUPI classification system had the lowest value in the 1-year c-index (0.590). In conclusion, the JIS system may be an appropriate staging system for HCC patients undergoing sorafenib therapy.
View Figures
View References

Related Articles

Journal Cover

April 2016
Volume 4 Issue 4

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Endo, M., Nishikawa, H., Kita, R., Kimura, T., Ohara, Y., Sakamoto, A. ... Osaki, Y. (2016). Comparison of five staging systems in hepatocellular carcinoma treated with sorafenib: A single-center experience. Molecular and Clinical Oncology, 4, 515-522. https://doi.org/10.3892/mco.2016.755
MLA
Endo, M., Nishikawa, H., Kita, R., Kimura, T., Ohara, Y., Sakamoto, A., Saito, S., Nishijima, N., Nasu, A., Komekado, H., Osaki, Y."Comparison of five staging systems in hepatocellular carcinoma treated with sorafenib: A single-center experience". Molecular and Clinical Oncology 4.4 (2016): 515-522.
Chicago
Endo, M., Nishikawa, H., Kita, R., Kimura, T., Ohara, Y., Sakamoto, A., Saito, S., Nishijima, N., Nasu, A., Komekado, H., Osaki, Y."Comparison of five staging systems in hepatocellular carcinoma treated with sorafenib: A single-center experience". Molecular and Clinical Oncology 4, no. 4 (2016): 515-522. https://doi.org/10.3892/mco.2016.755